Sertraline for the treatment of depression in parkinson's disease
Identifieur interne : 005265 ( Main/Exploration ); précédent : 005264; suivant : 005266Sertraline for the treatment of depression in parkinson's disease
Auteurs : Hauser [États-Unis] ; Theresa A. Zesiewicz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-09.
English descriptors
- KwdEn :
- 1-Naphthylamine (analogs & derivatives), 1-Naphthylamine (therapeutic use), Aged, Antidepressants, Antidepressive Agents, Second-Generation (therapeutic use), Antiparkinson Agents (therapeutic use), Depression, Depression (complications), Depression (drug therapy), Drug Interactions, Drug Therapy, Combination, Humans, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson's disease, Pilot Projects, Prospective Studies, Selegiline, Selegiline (therapeutic use), Serotonin Uptake Inhibitors (therapeutic use), Serotonin reuptake inhibitors, Sertraline, Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : 1-Naphthylamine.
- chemical , therapeutic use : 1-Naphthylamine, Antidepressive Agents, Second-Generation, Antiparkinson Agents, Selegiline, Serotonin Uptake Inhibitors.
- complications : Depression, Parkinson Disease.
- drug therapy : Depression, Parkinson Disease.
- Aged, Drug Interactions, Drug Therapy, Combination, Humans, Pilot Projects, Prospective Studies, Sertraline, Severity of Illness Index, Treatment Outcome.
Abstract
Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open‐label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit ˜7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean plusmn; SE = 16.0 plusmn; 2.0 vs 11.7 plusmn; 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy‐level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo‐controlled, double‐blind studies are warranted.
Url:
DOI: 10.1002/mds.870120522
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002B13
- to stream Istex, to step Curation: 002B13
- to stream Istex, to step Checkpoint: 003888
- to stream PubMed, to step Corpus: 004595
- to stream PubMed, to step Curation: 004595
- to stream PubMed, to step Checkpoint: 004580
- to stream Ncbi, to step Merge: 004D88
- to stream Ncbi, to step Curation: 004D88
- to stream Ncbi, to step Checkpoint: 004D88
- to stream Main, to step Merge: 008293
- to stream Main, to step Curation: 005265
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sertraline for the treatment of depression in parkinson's disease</title><author><name sortKey="Hauser" sort="Hauser" uniqKey="Hauser" last="Hauser">Hauser</name></author><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C5C5C572E9C896300A97CE27F517929F605113FE</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120522</idno><idno type="url">https://api.istex.fr/document/C5C5C572E9C896300A97CE27F517929F605113FE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B13</idno><idno type="wicri:Area/Istex/Curation">002B13</idno><idno type="wicri:Area/Istex/Checkpoint">003888</idno><idno type="wicri:doubleKey">0885-3185:1997:Hauser:sertraline:for:the</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9380061</idno><idno type="wicri:Area/PubMed/Corpus">004595</idno><idno type="wicri:Area/PubMed/Curation">004595</idno><idno type="wicri:Area/PubMed/Checkpoint">004580</idno><idno type="wicri:Area/Ncbi/Merge">004D88</idno><idno type="wicri:Area/Ncbi/Curation">004D88</idno><idno type="wicri:Area/Ncbi/Checkpoint">004D88</idno><idno type="wicri:doubleKey">0885-3185:1997:Hauser R:sertraline:for:the</idno><idno type="wicri:Area/Main/Merge">008293</idno><idno type="wicri:Area/Main/Curation">005265</idno><idno type="wicri:Area/Main/Exploration">005265</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sertraline for the treatment of depression in parkinson's disease</title><author><name sortKey="Hauser" sort="Hauser" uniqKey="Hauser" last="Hauser">Hauser</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-09">1997-09</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="756">756</biblScope><biblScope unit="page" to="759">759</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C5C5C572E9C896300A97CE27F517929F605113FE</idno><idno type="DOI">10.1002/mds.870120522</idno><idno type="ArticleID">MDS870120522</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Naphthylamine (analogs & derivatives)</term><term>1-Naphthylamine (therapeutic use)</term><term>Aged</term><term>Antidepressants</term><term>Antidepressive Agents, Second-Generation (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Depression</term><term>Depression (complications)</term><term>Depression (drug therapy)</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Pilot Projects</term><term>Prospective Studies</term><term>Selegiline</term><term>Selegiline (therapeutic use)</term><term>Serotonin Uptake Inhibitors (therapeutic use)</term><term>Serotonin reuptake inhibitors</term><term>Sertraline</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>1-Naphthylamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>1-Naphthylamine</term><term>Antidepressive Agents, Second-Generation</term><term>Antiparkinson Agents</term><term>Selegiline</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Pilot Projects</term><term>Prospective Studies</term><term>Sertraline</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open‐label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit ˜7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean plusmn; SE = 16.0 plusmn; 2.0 vs 11.7 plusmn; 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy‐level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo‐controlled, double‐blind studies are warranted.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region><settlement><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li></orgName></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser" sort="Hauser" uniqKey="Hauser" last="Hauser">Hauser</name></region><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005265 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005265 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C5C5C572E9C896300A97CE27F517929F605113FE
|texte= Sertraline for the treatment of depression in parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |